Advent Life Sciences

Showcasing the significance of two new funds

Amphista Therapeutics

Announcing the company’s Series A financing, leading to raised awareness with potential partners, investors and employees.

Amphista Therapeutics: Series B Financing

Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.

AnaMar AB

Refreshing the company's corporate comms portfolio and strategy, including revamp of existing materials and supporting interest in lead asset ahead of BIO International Convention.

AstraZeneca

Positioning the Company as a Partner of Choice as well as facilitating an Internal Change Management Programme.

BC Platforms

Positioning the company as a thought leader in precision medicine raising awareness with customers and investors.

ExeVir Bio EIB funding case study

Announcing the company's 25 million Euro financing from EIB to advance ExeVir’s COVID19 therapeutic

IRBM

Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.

Medicxi

To launch Index’s new spin-out life sciences fund and publicise its first closing.

Pneumagen

Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.

TILT Biotherapeutics €22 Million Financing

Supporting TILT Biotherapeutics and their final close of €22 Million financing

Vaccitech

Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.

Vaccitech IPO

Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing 

VaxEquity Strategic Collaboration with AstraZeneca

Announcing the company's strategic collaboration with AstraZeneca to Commercialise Self-Amplifying RNA platform

Advent Life Sciences

Showcasing the significance of two new funds

Amphista Therapeutics

Announcing the company’s Series A financing, leading to raised awareness with potential partners, investors and employees.

Amphista Therapeutics: Series B Financing

Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.

AnaMar AB

Refreshing the company's corporate comms portfolio and strategy, including revamp of existing materials and supporting interest in lead asset ahead of BIO International Convention.

AstraZeneca

Positioning the Company as a Partner of Choice as well as facilitating an Internal Change Management Programme.

BC Platforms

Positioning the company as a thought leader in precision medicine raising awareness with customers and investors.

ExeVir Bio EIB funding case study

Announcing the company's 25 million Euro financing from EIB to advance ExeVir’s COVID19 therapeutic

IRBM

Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.

Medicxi

To launch Index’s new spin-out life sciences fund and publicise its first closing.

Pneumagen

Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.

TILT Biotherapeutics €22 Million Financing

Supporting TILT Biotherapeutics and their final close of €22 Million financing

Vaccitech

Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.

Vaccitech IPO

Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing 

VaxEquity Strategic Collaboration with AstraZeneca

Announcing the company's strategic collaboration with AstraZeneca to Commercialise Self-Amplifying RNA platform